Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER.
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, leading to cell lysis and death. It has activity against both gram-positive and gram-negative bacteria.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
1-2 g intravenously every 8-12 hours; typical dose 1 g IV q12h for most infections, 2 g IV q8h for severe infections.
None Documented
None Documented
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Approximately 2 hours in adults with normal renal function; prolonged to 4–8 hours in mild-to-moderate renal impairment and up to 13–30 hours in severe impairment (CrCl <30 mL/min).
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
Primarily renal (≥85% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal excretion minimal (<1%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic